CA Patent

CA3221390A1 — Sulfur-containing heteroaromatic tricyclic kras inhibitors

Assigned to Erasca Inc · Expires 2022-12-01 · 3y expired

What this patent protects

The present embodiments provide compounds of Formula I, pharmaceutical compositions of the compounds, and methods for treating diseases such as cancer.

USPTO Abstract

The present embodiments provide compounds of Formula I, pharmaceutical compositions of the compounds, and methods for treating diseases such as cancer.

Drugs covered by this patent

Patent Metadata

Patent number
CA3221390A1
Jurisdiction
CA
Classification
—
Expires
2022-12-01
Drug substance claim
No
Drug product claim
No
Assignee
Erasca Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.